Cancer Clinical Trials

Breast

  • Alliance A011202 - A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

  • ECOG 2112 - A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer

  • ECOG-ACRIN EA1141 - Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

  • Puma Puma-NER-6201 - An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

  • RTOG 1304 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Digestive/Gastrointenstinal

  • BMS CA209-577 - A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer

  • BMS CA209-648 - A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

  • RTOG 1112 - Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib in Hepatocellular Carcinoma

Genetics

  • ECOG-ACRIN EAY-131 - A Trial That Aims to Establish Whether Patients With Tumor Mutations, Amplifications Or Translocations in One of the Genetic Pathways of Interest Are Likely to Derive Clinical Benefit If Treated With Agents Targeting That Specific Pathway In A Single-Arm Design

Genitourinary

  • Bayer REASSURE - Radium-223 Alpha Emitter Agent in Non-Intervention Safety Study in mCRPC Population for Long-Term Evaluation

Gynecologic

  • GOG 0225 - Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube And Primary Peritoneal Cancer Progression-Free Survival?

Hematologic/Blood

  • Pharmacyclics PCYC-1134M-CA - informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

Other

  • Accuray ReCKord - CyberKnife Registry Protocol

Respiratory/Thoracic

  • Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

  • JoLT-Ca STU 022015-069 - A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

  • Oncocyte PRO068 - A Study to Evaluate a Panel of Blood Biomarkers For Use In Patients Undergoing Evaluation For Lung Cancer, ONC-LN-04

  • OSE Immunotherapeutics OSE2101C301 - A Randomized Parallel Group Phase III Trial of OSE 2101 as 2nd Line After Prior Platinum-Based Chemotherapy Failure or as 3rd Line After Platinum-Failure and Checkpoint Inhibitor-Failure, Compared With Standard Treatment (Docetaxel or Pemetrexed) In HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable For Radiotherapy or Metastatic Non-Small-Cell Lung Cancer. (OSE2101C301)

  • SWOG S1400 - Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (LUNG-MAP)

  • Wistar Institute 20171814 - Identification of Cancer Markers in Samples of Peripheral Blood

Skin

  • ECOG-ACRIN EA6134 - A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab At Progression vs. Ipilimumab + Nivolumab Followed By Dabrafenib + Trametinib At Progression in Patients With Advanced BRAFV600 Mutant Melanoma